XML 21 R11.htm IDEA: XBRL DOCUMENT
v3.23.1

Statements of Operations-Additional Information | 9 Months Ended
--- | ---
Mar. 31, 2023
Statements of Operations-Additional Information |
Disaggregated Revenue, Deferred Revenue and Customer Payment Terms | Disaggregated revenue, deferred revenue and customer payment terms We develop, manufacture and market a broad range of products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. The products help prevent, control and treat diseases and support nutrition to help improve animal health and well-being. The animal health and mineral nutrition products are sold directly to integrated poultry, cattle, and swine customers and through commercial animal feed manufacturers, wholesalers, distributors and veterinarians. The animal health industry and demand for many of the animal health products in a particular region are affected by changing disease pressures and by weather conditions, as product usage follows varying weather patterns and seasons. Our operations are primarily focused on regions where the majority of livestock production is consolidated in large commercial farms. We have a diversified portfolio of products that are classified within our three business segments—Animal Health, Mineral Nutrition and Performance Products. Each segment has its own dedicated management and sales team. Animal Health The Animal Health business develops, manufactures and markets products in three main categories:
| ● | MFAs and other: MFAs and other products primarily consist of concentrated medicated products that are administered through animal feeds, commonly referred to as Medicated Feed Additives (“MFAs”). Specific product classifications include antibacterials, which inhibit the growth of pathogenic bacteria that cause bacterial infections in animals; anticoccidials, which inhibit the growth of coccidia (parasites) that damage the intestinal tract of animals; and other related products. The MFAs and other category also includes other antibacterial products and processing aids used in the ethanol fermentation industry.
| ● | Nutritional specialties: Nutritional specialty products enhance nutrition to help improve health and performance in areas such as immune system function and digestive health. We are also a developer, manufacturer and marketer of microbial products and bioproducts for a variety of applications serving animal health and nutrition, environmental, industrial and agricultural customers.
| ● | Vaccines: Vaccine products are primarily focused on preventing diseases in poultry and swine. They protect animals from either viral or bacterial disease challenges. We develop, manufacture and market conventionally licensed and
|  | autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. We have also developed and market an innovative and proprietary delivery platform for vaccines.
Mineral Nutrition The Mineral Nutrition business is comprised of formulations and concentrations of trace minerals such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Our customers use these products to fortify the daily feed requirements of their livestock’s diets and maintain an optimal balance of trace elements in each animal. We manufacture and market a broad range of mineral nutrition products for food animals including poultry, swine, and beef and dairy cattle. Performance Products The Performance Products business manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries. The following tables present our revenues disaggregated by major product category and geographic region: Net Sales by Product Type ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months | ​ | Nine Months
For the Periods Ended March 31 |  | 2023 |  | 2022 |  | 2023 |  | 2022
Animal Health |  | ​ |  |  | ​ |  | ​ | ​ |  |  | ​ |
MFAs and other | ​ | $ | 93,217 | ​ | $ | 84,330 | ​ | $ | 283,186 | ​ | $ | 259,812
Nutritional specialties | ​ |  | 45,016 | ​ |  | 41,394 | ​ |  | 127,926 | ​ |  | 114,721
Vaccines | ​ |  | 26,201 | ​ |  | 22,865 | ​ |  | 71,984 | ​ |  | 65,987
Total Animal Health | ​ | $ | 164,434 | ​ | $ | 148,589 | ​ | $ | 483,096 | ​ | $ | 440,520
Mineral Nutrition | ​ |  | 62,922 | ​ |  | 69,033 | ​ |  | 184,212 | ​ |  | 190,120
Performance Products | ​ |  | 18,317 | ​ |  | 21,997 | ​ |  | 55,532 | ​ |  | 56,356
Total | ​ | $ | 245,673 | ​ | $ | 239,619 | ​ | $ | 722,840 | ​ | $ | 686,996
​ Net Sales by Region ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months | ​ | Nine Months
For the Periods Ended March 31 |  | 2023 |  | 2022 |  | 2023 |  | 2022
United States | ​ | $ | 148,529 | ​ | $ | 146,820 | ​ | $ | 433,716 | ​ | $ | 412,284
Latin America and Canada | ​ |  | 53,881 | ​ |  | 45,048 | ​ |  | 159,946 | ​ |  | 135,722
Europe, Middle East and Africa | ​ |  | 28,174 | ​ |  | 29,931 | ​ |  | 85,518 | ​ |  | 90,889
Asia Pacific | ​ |  | 15,089 | ​ |  | 17,820 | ​ |  | 43,660 | ​ |  | 48,101
Total | ​ | $ | 245,673 | ​ | $ | 239,619 | ​ | $ | 722,840 | ​ | $ | 686,996
​ ​ Net sales by region are based on country of destination. Deferred revenue was $1,479 and $2,051 as of March 31, 2023 and June 30, 2022, respectively. Accrued expenses and other current liabilities included $508 and $822 of the total deferred revenue as of March 31, 2023 and June 30, 2022, respectively. The deferred revenue resulted primarily from certain customer arrangements, including technology licensing fees and discounts on future product sales. The transaction price associated with our deferred revenue arrangements is generally based on the stand-alone sales prices of the individual products or services. Our customer payment terms generally range from 30 to 120 days globally and exclude any significant financing components. Payment terms vary based on industry and business practices within the regions in which we operate. Our average worldwide collection period for accounts receivable is approximately 60 days after the revenue is recognized. ​
Additional Information | Interest Expense ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months | ​ | Nine Months
For the Periods Ended March 31 |  | 2023 |  | 2022 |  | 2023 |  | 2022
Interest expense, net | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2021 Term A loan | ​ | $ | 1,450 | ​ | $ | 2,208 | ​ | $ | 4,836 | ​ | $ | 6,745
Revolving credit facility | ​ |  | 3,067 | ​ |  | 690 | ​ |  | 7,480 | ​ |  | 1,936
2022 Term loan | ​ | ​ | 191 | ​ | ​ | — | ​ | ​ | 379 | ​ | ​ | —
Amortization of debt issuance costs | ​ |  | 188 | ​ |  | 147 | ​ |  | 514 | ​ |  | 442
Other | ​ |  | 10 | ​ |  | 67 | ​ |  | 20 | ​ |  | 156
Interest expense | ​ |  | 4,906 | ​ |  | 3,112 | ​ |  | 13,229 | ​ |  | 9,279
Interest income | ​ |  | (1,035) | ​ |  | (187) | ​ |  | (2,407) | ​ |  | (512)
​ | ​ | $ | 3,871 | ​ | $ | 2,925 | ​ | $ | 10,822 | ​ | $ | 8,767
​ ​ Depreciation and Amortization ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months | ​ | Nine Months
For the Periods Ended March 31 |  | 2023 |  | 2022 |  | 2023 |  | 2022
Depreciation and amortization | ​ |  | ​ | ​ |  |  | ​ |  | ​ | ​ |  |
Depreciation of property, plant and equipment | ​ | $ | 6,067 | ​ | $ | 6,214 | ​ | $ | 18,177 | ​ | $ | 17,792
Amortization of intangible assets | ​ |  | 2,422 | ​ |  | 2,231 | ​ |  | 7,261 | ​ |  | 6,508
​ | ​ | $ | 8,489 | ​ | $ | 8,445 | ​ | $ | 25,438 | ​ | $ | 24,300
​ ​ ​

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_IncomeStatementRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI https://asc.fasb.org/topic&trid=49130388 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 12 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration